Education Archive

FUTURE I/II trial shows sustained HPV vaccine efficacy

FUTURE (Females United To Unilaterally Reduce Endo-ectocervical disease) was a randomized controlled trial studying the efficacy of the quadrivalent HPV vaccine Gardasil. The trial involved nearly 18000 women in 24 countries. The vaccine provided sustained protection (>95%) against low grade lesions attributable to vaccine HPV types (6, 11, 16, and 18) and a substantial reduction in the burden of these diseases through 42 months of follow-up. Protection against all low grade lesions (regardless of HPV type) was also sgnificant (30%, 75% and 48% for cervical, vulval and vaginal lesions, respectively).